Italia markets open in 3 hours 38 minutes

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
9,83-0,42 (-4,10%)
Alla chiusura: 04:00PM EST
9,99 +0,16 (+1,63%)
Dopo ore: 07:05PM EST

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno264

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. James C. MullenExec. Chairman1,01MN/D1959
Ms. Michelle RobertsonCFO, Principal Accounting Officer, Treasurer & Assistant Sec.641,74k101,88k1967
Dr. Mark S. ShearmanExec. VP & Chief Scientific Officer639,89kN/D1960
Dr. Bruce E. Eaton Ph.D.Exec. VP & Chief Bus. Officer1,09MN/D1954
Dr. Gilmore O'NeillPres & CEON/DN/D1964
Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/DN/D
Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/D1954
Dr. J. Keith Joung M.D., Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/DN/D
Dr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberN/DN/DN/D
Mr. Harry R. Gill IIISr. VP of OperationsN/DN/D1961
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Editas Medicine, Inc. al 1 dicembre 2022 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.